SCHEMBL3735455

SCHEMBL3735455

Cc1ccc(-c2ccc(C=CC(=O)O)cc2)nc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.65
ALDH1A1 P00352 4/20 0.65
HPGD P15428 4/20 0.65
SMN1; SMN2 Q16637 2/20 0.65
MITF O75030 1/20 0.65
KLF5 Q13887 1/20 0.65
RAB9A P51151 4/20 0.61
NPC1 O15118 2/20 0.61
CASP3 P42574 1/20 0.61
SENP8 Q96LD8 1/20 0.61
SENP7 Q9BQF6 1/20 0.61
SENP6 Q9GZR1 1/20 0.61
P4HTM Q9NXG6 1/20 0.46
IP6K1 Q92551 1/20 0.46
IP6K3 Q96PC2 1/20 0.46
IP6K2 Q9UHH9 1/20 0.46
HCAR2 Q8TDS4 2/20 0.46
ESR1 P03372 2/20 0.46
CA12 O43570 1/20 0.46
AKR1B10 O60218 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3735450 1.00 KDM4E (0.65) KDM4EALDH1A1HPGDSMN1; SMN2MITF
SCHEMBL1845172 0.82 CA12 (0.57) KDM4EALDH1A1HPGDSMN1; SMN2MITF
SCHEMBL14115800 0.82 KDM4E (0.61) KDM4EALDH1A1HPGDSMN1; SMN2MITF
SCHEMBL14115802 0.82 KDM4E (0.61) KDM4EALDH1A1HPGDSMN1; SMN2MITF
SCHEMBL11826245 0.80 FOS (0.59) KDM4EALDH1A1HPGDRAB9AIP6K1
SCHEMBL1510040 0.80 FOS (0.59) KDM4EALDH1A1HPGDRAB9AIP6K1
SCHEMBL5293356 0.80 ALDH1A1 (0.62) KDM4EALDH1A1HPGDSMN1; SMN2MITF
SCHEMBL5293348 0.80 ALDH1A1 (0.62) KDM4EALDH1A1HPGDSMN1; SMN2MITF
SCHEMBL13429919 0.79 SMN1; SMN2 (1.00) KDM4EALDH1A1HPGDSMN1; SMN2MITF
SCHEMBL3611594 0.79 KDM4E (0.61) KDM4EALDH1A1HPGDSMN1; SMN2MITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846910-B2 Matrix metalloproteinase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2014-09-30 US disclosed
US-8816073-B2 Matrix metalloproteinase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2014-08-26 US disclosed
US-20130302378-A1 MATRIX METALLOPROTEINASE INHIBITORS SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2013-11-14 US disclosed
US-20130295141-A1 MATRIX METALLOPROTEINASE INHIBITORS SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2013-11-07 US disclosed
US-8507670-B2 Matrix metalloproteinase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2013-08-13 US disclosed
EP-2074093-B1 PROCESS FOR PREPARING MATRIX METALLOPROTEINASE INHIBITORS AND CHIRAL AUXILIARY THEREFOR RANBAXY LAB LTD (IN) 2012-10-10 EP disclosed
EP-2474531-A2 Matrix metalloproteinase inhibitors Ranbaxy Laboratories Limited (IN) 2012-07-11 EP disclosed
US-20100081610-A1 MATRIX METALLOPROTEINASE INHIBITORS SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2010-04-01 US disclosed
EP-2074093-A2 MATRIX METALLOPROTEINASE INHIBITORS Ranbaxy Laboratories Limited (IN) 2009-07-01 EP disclosed
WO-2008023336-A2 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130302378-A1 MATRIX METALLOPROTEINASE INHIBITORS MMP9, MMP8, MMP25 KDM4E 3545/4885ALDH1A1 985/4885HPGD 65/4885
US-20130295141-A1 MATRIX METALLOPROTEINASE INHIBITORS MMP9, MMP8, MMP25 KDM4E 3545/4885ALDH1A1 985/4885HPGD 65/4885
US-20100081610-A1 MATRIX METALLOPROTEINASE INHIBITORS MMP9, MMP8, MMP12 KDM4E 3523/4885ALDH1A1 1056/4885HPGD 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.